TY - JOUR T1 - Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement JF - Anticancer Research JO - Anticancer Res SP - 871 LP - 876 VL - 38 IS - 2 AU - CHRISTINE D. VALAN AU - JENS E. SLAGSVOLD AU - TARJE ONSØIEN HALVORSEN AU - MARTIN HERJE AU - ROY M. BREMNES AU - PAAL F. BRUNSVIG AU - ODD T. BRUSTUGUN AU - ØYSTEIN FLØTTEN AU - NINA LEVIN AU - STEIN H. SUNDSTRØM AU - BJØRN H. GRØNBERG Y1 - 2018/02/01 UR - http://ar.iiarjournals.org/content/38/2/871.abstract N2 - Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and Methods: Patients with a baseline CT scan available were analysed. Patients received four courses of cisplatin/etoposide and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). Results: Median overall survival (OS) was 23.3 months in the whole cohort. N3-patients (n=37) had shorter survival than those with N0-2 (16.7 vs. 33.0 months; p<0.001). There were no significant OS-differences between the N3 subcategories, but patients with metastases to two or more N3 regions had shorter survival than other N3 patients (13.4 vs. 19.9 months; p=0.011). Conclusion: There were no survival differences between the N3 subcategories, suggesting that all N3 disease should be considered as LD. ER -